Free Trial

Boston Scientific (BSX) to Release Earnings on Wednesday

Boston Scientific logo with Medical background

Key Points

  • Boston Scientific is set to release its Q3 2025 earnings on October 22, 2025, with expectations of $0.71 per share and $4.9663 billion in revenue.
  • In the previous quarter, Boston Scientific reported an EPS of $0.75, surpassing estimates, and achieving a 22.8% revenue increase year-over-year.
  • Recent upgrades from analysts have increased the price targets for Boston Scientific's stock, with a consensus rating of "Buy" and an average price target of $120.71.
  • Five stocks we like better than Boston Scientific.

Boston Scientific (NYSE:BSX - Get Free Report) will likely be issuing its Q3 2025 results before the market opens on Wednesday, October 22nd. Analysts expect the company to announce earnings of $0.71 per share and revenue of $4.9663 billion for the quarter. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS.Parties may visit the the company's upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, October 22, 2025 at 8:00 AM ET.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the previous year, the business posted $0.62 EPS. The company's quarterly revenue was up 22.8% compared to the same quarter last year. On average, analysts expect Boston Scientific to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Boston Scientific Trading Up 1.4%

NYSE:BSX opened at $96.26 on Wednesday. Boston Scientific has a one year low of $80.64 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The firm has a market cap of $142.63 billion, a P/E ratio of 57.30, a P/E/G ratio of 2.29 and a beta of 0.61. The firm has a 50-day simple moving average of $101.58 and a 200-day simple moving average of $101.80.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. BTIG Research boosted their price objective on shares of Boston Scientific from $127.00 to $132.00 and gave the stock a "buy" rating in a research note on Wednesday, October 1st. Barclays boosted their price target on Boston Scientific from $133.00 to $136.00 and gave the stock an "overweight" rating in a research report on Thursday, October 2nd. Oppenheimer upgraded shares of Boston Scientific from a "market perform" rating to an "outperform" rating and boosted their target price for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Erste Group Bank downgraded shares of Boston Scientific from a "buy" rating to a "hold" rating in a report on Friday, October 3rd. Finally, Truist Financial boosted their price objective on shares of Boston Scientific from $125.00 to $129.00 and gave the stock a "buy" rating in a research note on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $120.71.

Check Out Our Latest Stock Analysis on BSX

Insider Transactions at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,469,268. This represents a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares in the company, valued at $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $17,972,457 in the last quarter. Insiders own 0.50% of the company's stock.

Institutional Trading of Boston Scientific

Several hedge funds and other institutional investors have recently bought and sold shares of BSX. Brighton Jones LLC grew its holdings in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after acquiring an additional 226 shares during the period. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific during the 2nd quarter worth approximately $26,000. Main Street Financial Solutions LLC grew its stake in shares of Boston Scientific by 35.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider's stock worth $812,000 after purchasing an additional 1,971 shares during the period. Ieq Capital LLC grew its position in Boston Scientific by 97.0% during the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider's stock valued at $13,275,000 after buying an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC grew its position in Boston Scientific by 56.2% during the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider's stock valued at $763,000 after buying an additional 2,556 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

About Boston Scientific

(Get Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Featured Articles

Earnings History for Boston Scientific (NYSE:BSX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Boston Scientific Right Now?

Before you consider Boston Scientific, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.

While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.